Literature DB >> 31633232

IL-35, a double-edged sword in cancer.

Zahra Yazdani1, Alireza Rafiei1, Monireh Golpour2, Parisa Zafari1,2, Mohammadreza Moonesi3, Sasan Ghaffari4,5.   

Abstract

Interleukin 35 (IL-35), a cytokine mainly produced by regulatory T cells (Treg cells), is composed of an Epstein-Barr virus-induced gene 3 β-chain and an IL-12 p35 α-chain. IL-35 causes tumorigenicity in cancer, protects cancer cells against apoptosis, and facilitates cancer progression. However, a few reports have referred to its contradictory roles in cancer prevention. Therefore, the exact purpose of this cytokine in cancer development has become a fundamental question that needs to be answered. In this review, we explain the structure of IL-35 and its receptors and their different signaling pathways. Finally, the function of IL-35 in some cancers and the possible application of this cytokine in approaches for cancer therapy have been discussed.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  IL-12 family; cancer; interleukin-35; regulatory B cells; regulatory T cells

Mesh:

Substances:

Year:  2019        PMID: 31633232     DOI: 10.1002/jcb.29441

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

Review 1.  Granulocyte-colony stimulating factor (G-CSF): an emerging therapeutic approach for amyotrophic lateral sclerosis (ALS).

Authors:  Mahsa Vafaei Mastanabad; Aref Nooraei; Mahgol Sadat Hassan Zadeh Tabatabaei; Amir Akbari Fakhrabadi; Faria Jafarzadeh
Journal:  Acta Neurol Belg       Date:  2022-06-23       Impact factor: 2.396

Review 2.  Autophagy-related signaling pathways in non-small cell lung cancer.

Authors:  Jing Wang; Mei Gong; Xirong Fan; Dalu Huang; Jinshu Zhang; Cheng Huang
Journal:  Mol Cell Biochem       Date:  2021-11-10       Impact factor: 3.396

Review 3.  Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies.

Authors:  Mohammad Salemizadeh Parizi; Fatemeh Salemizadeh Parizi; Saeed Abdolhosseini; Shohreh Vanaei; Ali Manzouri; Farnoosh Ebrahimzadeh
Journal:  Inflammopharmacology       Date:  2021-10-06       Impact factor: 4.473

Review 4.  The TRIM proteins in cancer: from expression to emerging regulatory mechanisms.

Authors:  A Mohammadi; M S Pour Abbasi; S Khorrami; S Khodamoradi; Z Mohammadi Goldar; F Ebrahimzadeh
Journal:  Clin Transl Oncol       Date:  2021-10-13       Impact factor: 3.405

Review 5.  Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.

Authors:  Bhalchandra Mirlekar
Journal:  SAGE Open Med       Date:  2022-01-25

6.  Serum IL-35 levels is a new candidate biomarker of cancer-related cachexia in stage IV non-small cell lung cancer.

Authors:  Lei Zhu; Han Zheng; Zengxun Li; Wenna Jiang; Yifei Wang; Zhansheng Jiang; Jie Xu
Journal:  Thorac Cancer       Date:  2022-02-09       Impact factor: 3.500

7.  Interleukin-35 attenuates blood-brain barrier dysfunction caused by cerebral ischemia-reperfusion injury through inhibiting brain endothelial cell injury.

Authors:  Lei Qian; Ming Li; Xin Lin; Hongwei Teng; Lulu Yu; Maorong Jiang
Journal:  Ann Transl Med       Date:  2022-07

Review 8.  IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.

Authors:  Kewei Liu; Ai Huang; Jun Nie; Jun Tan; Shijie Xing; Yue Qu; Ke Jiang
Journal:  Front Immunol       Date:  2021-05-21       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.